HIV Clinical trials in Bihar.

[Guest guest]

HIV Clinical trials in Bihar.

(AIeF) Aethlon Medical, Inc. announced that it has added a second

HIV/AIDS clinical study location at the Bhvani Hospital in Bihar,

India.

Aethlon previously disclosed plans to initiate the " first-in-man "

clinical study of a medical device to treat the Human

Immunodeficiency Virus (HIV), which causes Acquired Immune Deficiency

Syndrome (AIDS).

The Aethlon Hemopurifier is a medical device created to provide real-

time therapeutic filtration of infectious viruses and

immunosuppressive proteins. The Hemopurifier holds promise to extend

the lives of AIDS patients by removing HIV strains that cause drug

failure and reducing the presence of viral proteins that kill-off

immune cells.

On June 24th, Aethlon announced that its first HIV/AIDS treatment

study had been approved by the Institutional Ethics Committee at

Jattinder Gambhir Hospital (J.G. Hospital) in Punjab, India. Clinical

studies at both site locations are anticipated to begin in September.

Aethlon Medical is the developer of the Hemopurifier, a first-in-

class medical device designed to treat infectious disease.

Aethlon claims their new instrument, the Hemopurifier provides real-

time therapeutic filtration of infectious viruses and

immunosuppressive particles, and is positioned to address the

treatment of drug and vaccine resistant viruses. Additionally, they

claims, the device holds promise in cancer care, as research studies

have verified the Hemopurifier is able to capture immunosuppressive

particles secreted by tumors.

The Hemopurifier is designed to act both as a stand-alone

therapeutic, and as an adjunct treatment to enhance clinical benefit

of established therapies. Pre-clinical studies conducted by

researchers representing leading government and non-government health

organizations both in the United States and abroad have documented

the effectiveness of the Hemopurifier in capturing from circulation

the viruses that constitute pandemic threats, including H5N1 Avian

Influenza (bird flu), and Dengue Hemorrhagic Fever from circulation.

Aethlon claims that it demonstrated the safety of the Hemopurifier in

a 24-treatment human study at the Apollo Hospital in Delhi, India,

and is currently conducting further human studies at the Fortis

Hospital, also located in Delhi.

The company has submitted an investigational device exemption (IDE)

to the U.S. Food and Drug Administration (FDA) to advance the

Hemopurifier as a broad-spectrum treatment countermeasure against

category " A " bioterror threats.

Ref:

Aethlon Medical, Inc.

A. Joyce, Chairman, CEO

619-368-2000, jj@...

www.aethlonmedical.com.

http://www.foxbusiness.com/story/markets/industries/health-

care/aethlon-medical-announces-second-hivaids-treatment-site/